AFFILIATIONS
1 Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Hangzhou, China, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, China, Zhejiang University Cancer Center, Hangzhou, China
2 Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Hangzhou, China, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, China, Zhejiang University Cancer Center, Hangzhou, China
3 Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Hangzhou, China, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, China, Zhejiang University Cancer Center, Hangzhou, China
4 Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Hangzhou, China, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, China, Zhejiang University Cancer Center, Hangzhou, China
5 Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Hangzhou, China, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, China, Zhejiang University Cancer Center, Hangzhou, China
6 Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Hangzhou, China, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, China, Zhejiang University Cancer Center, Hangzhou, China
7 Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Hangzhou, China, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, China, Zhejiang University Cancer Center, Hangzhou, China
8 Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Hangzhou, China, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, China, Zhejiang University Cancer Center, Hangzhou, China
9 Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Hangzhou, China, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, China, Zhejiang University Cancer Center, Hangzhou, China
ABSTRACT
Introduction
Chimeric antigen receptor T-cell (CAR T) therapy and autologous stem cell transplantation can elicit durable remissions in selected patients with R/R DLBCL. However, patient and treatment issues such as fitness, access, timing, or preference preclude use of these treatment modalities in many individuals, leaving them with few later-line options. Homoharringtonine (HHT) inhibits oncoprotein synthesis and rapidly reduces the short-lived antiapoptotic protein MCL-1, providing a mechanistic rationale for complementary targeting with the selective BCL-2 inhibitor lisaftoclax. Lisaftoclax is approved in China for previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma; its use in DLBCL remains investigational. We initiated this study to evaluate the safety, tolerability, and feasible dosing of the combination of HHT with lisaftoclax in patients with R/R DLBCL.
Methods
This ongoing, prospective, single-arm, investigator-initiated phase 1b/2 study (NCT07159906) uses a 3+3 design with 5 planned HHT dose levels in a lisaftoclax-based regimen. Primary objectives are to evaluate dose-limiting toxicities (DLTs), safety, and tolerability and determine the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D). Assessing antitumor activity is an exploratory objective. The DLT window is cycle 1; adverse events (AEs) are graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Responses were investigator-assessed using available imaging (PET/CT, CT, MRI, or serial ultrasonography), with the modality documented for each assessment.
Results
At data cutoff (July 20, 2026), 11 treated patients were included in safety and efficacy analyses. The median age was 67 years (range, 46-76), and 6 of 11 patients (54.5%) were male. A total of 23 study-treatment cycles were administered, with a median of 2 cycles per patient (range, 1-4). No DLT was observed. Dose escalation remained ongoing, and the MTD/RP2D had not been established at cutoff. Grade ≥3 neutropenia and thrombocytopenia occurred in 7/11 (63.6%) and 1/11 (9.1%), respectively. A grade 3 pulmonary infection, recorded as an SAE, delayed the next cycle in 1 patient, improved after treatment, and did not meet DLT criteria. No clinical TLS was reported; laboratory TLS was not systematically captured. Exploratory best overall response was complete response (CR) in 1 patient, partial response (PR) in 4, stable disease in 1, and progressive disease in 5. The objective response rate was 45.5% (5/11), and the CR rate was 9.1% (1/11). Response follow-up remained immature, and duration of response was not estimated.
Conclusions
HHT plus lisaftoclax-based therapy showed preliminary antitumor activity in R/R DLBCL during dose escalation. Grade ≥3 hematologic AEs, predominantly neutropenia, were the main safety signal; no DLT or treatment-related death was observed. Further enrollment with standardized response assessment is needed to establish the RP2D and clarify response durability.